X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs CIPLA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER CIPLA PFIZER/
CIPLA
 
P/E (TTM) x 32.9 38.3 86.0% View Chart
P/BV x 4.9 3.9 124.4% View Chart
Dividend Yield % 0.8 0.3 236.8%  

Financials

 PFIZER   CIPLA
EQUITY SHARE DATA
    PFIZER
Mar-17
CIPLA
Mar-17
PFIZER/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,055622 330.4%   
Low Rs1,651458 360.3%   
Sales per share (Unadj.) Rs429.8181.9 236.3%  
Earnings per share (Unadj.) Rs73.612.9 572.0%  
Cash flow per share (Unadj.) Rs87.429.3 298.0%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.10.4 291.5%  
Book value per share (Unadj.) Rs528.7155.7 339.6%  
Shares outstanding (eoy) m45.75804.51 5.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.33.0 145.2%   
Avg P/E ratio x25.242.0 60.0%  
P/CF ratio (eoy) x21.218.4 115.1%  
Price / Book Value ratio x3.53.5 101.0%  
Dividend payout %27.215.5 174.8%   
Avg Mkt Cap Rs m84,777434,516 19.5%   
No. of employees `0002.823.0 12.3%   
Total wages/salary Rs m3,03926,338 11.5%   
Avg. sales/employee Rs Th6,925.96,349.1 109.1%   
Avg. wages/employee Rs Th1,070.41,143.0 93.6%   
Avg. net profit/employee Rs Th1,186.3449.3 264.0%   
INCOME DATA
Net Sales Rs m19,663146,302 13.4%  
Other income Rs m1,0122,287 44.2%   
Total revenues Rs m20,674148,589 13.9%   
Gross profit Rs m3,49124,758 14.1%  
Depreciation Rs m62913,229 4.8%   
Interest Rs m101,594 0.6%   
Profit before tax Rs m3,86412,222 31.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,8011,798 100.2%   
Profit after tax Rs m3,36810,354 32.5%  
Gross profit margin %17.816.9 104.9%  
Effective tax rate %46.614.7 316.8%   
Net profit margin %17.17.1 242.0%  
BALANCE SHEET DATA
Current assets Rs m20,78987,370 23.8%   
Current liabilities Rs m7,87033,081 23.8%   
Net working cap to sales %65.737.1 177.1%  
Current ratio x2.62.6 100.0%  
Inventory Days Days6087 68.7%  
Debtors Days Days2262 36.0%  
Net fixed assets Rs m9,175111,567 8.2%   
Share capital Rs m4581,609 28.4%   
"Free" reserves Rs m23,731123,645 19.2%   
Net worth Rs m24,189125,254 19.3%   
Long term debt Rs m2536,454 0.1%   
Total assets Rs m32,706209,532 15.6%  
Interest coverage x403.58.7 4,654.9%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.60.7 86.1%   
Return on assets %10.35.7 181.1%  
Return on equity %13.98.3 168.4%  
Return on capital %21.48.5 251.6%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m6351,066 0.1%   
Fx outflow Rs m4,06717,678 23.0%   
Net fx Rs m-4,00433,388 -12.0%   
CASH FLOW
From Operations Rs m3,28823,824 13.8%  
From Investments Rs m-2,496-13,127 19.0%  
From Financial Activity Rs m-826-13,239 6.2%  
Net Cashflow Rs m-35-2,478 1.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 63.9 20.8 307.2%  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 4.9 23.7 20.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.7 26.2 90.5%  
Shareholders   85,207 161,166 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   AUROBINDO PHARMA  MERCK LTD  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 22, 2018 (Close)

TRACK PFIZER

PFIZER - PANACEA BIOTECH COMPARISON

COMPARE PFIZER WITH

MARKET STATS